ITEMS IN AFP WITH KEYWORD:
The Prolaris test improves the accuracy of prognosis for patients with prostate cancer, especially those with low- or intermediate-grade disease who may be deciding between interventional and noninterventional treatment approaches.
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.
The AAFP finds that the net benefit of population screening for prostate cancer is small at best, and it does not recommend routinely discussing PSA-based screening if the patient does not request it.
A.E., a 57-year-old black man, comes to your office for an annual visit. He has a history of diabetes mellitus, has never smoked, and has no family history of prostate cancer. He is current with preventive services, including screening for colorectal cancer and counseling for a healthy diet and phys...
Oct 15, 2018 Issue
Screening for Prostate Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
Because prostate cancer is often slow-growing and treatment can cause adverse effects, some patients may choose active surveillance over curative treatments such as radiation therapy or surgery. Each option has advantages and disadvantages, and there are few studies comparing their outcomes. Ttreatment choices should be individualized and made through shared decision making.
This landmark study compared active surveillance with radical prostatectomy or radiation therapy for patients with T1c or T2 prostate cancer. The benefits of active surveillance include avoiding radical therapy in one-half of the patients, with no effect on disease-specific survival or all-cause sur...
For family physicians to put PSA screening guidance into practice, they must elicit patients' preferences and provide accurate, understandable information about the benefits and harms.
This summary of the American Cancer Society Prostate Cancer Survivorship Care Guidelines provides recommended management approaches for physical and pschosocial issues facing patients after treatment.
Despite variations across guidelines, no organization recommends routine prostate-specific antigen testing to screen for prostate cancer, and most endorse decision-making between the patient and physician or no screening.